Percutaneous ablation of hepatocellular carcinoma: current status.
Hepatocellular carcinoma (HCC) is an increasingly common disease with dismal long-term survival. Percutaneous ablation has gained popularity as a minimally invasive, potentially curative therapy for HCC in nonoperative candidates. The seminal technique of percutaneous ethanol injection has been largely supplanted by newer modalities, including radiofrequency ablation, microwave ablation, cryoablation, and high-intensity focused ultrasound ablation. A review of these modalities, including technical success, survival rates, and complications, will be presented, as well as considerations for treatment planning and follow-up.
McWilliams
Justin P
JP
Department of Interventional Radiology, University of California Los Angeles Medical Center, 757 Westwood Plaza, Suite 2125C, Los Angeles, CA 90095, USA. jumcwilliams@mednet.ucla.edu
Yamamoto
Shota
S
Raman
Steven S
SS
Loh
Christopher T
CT
Lee
Edward W
EW
Liu
David M
DM
Kee
Stephen T
ST
D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000295:instrumentation; D003452:Cryosurgery; D004867:Equipment Design; D000431:Ethanol / Q000008:administration & dosage; D057086:High-Intensity Focused Ultrasound Ablation; D006801:Humans; D007267:Injections; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008872:Microwaves / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D018579:Patient Selection; D016896:Treatment Outcome
D000431:Ethanol